Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1629 1654
This examiner grants 64% of resolved cases
Alison Azar Hastings is an examiner in Tech Center 1600, working in Art Unit 1627. She has overseen 85 resolved cases, and her allowance rate is 63.5 percent. This is a favorable rate for applicants, suggesting a probability of securing a patent grant. The data provides a benchmark for practitioners to evaluate their chances of success. The 85 resolved cases offer a clear view of the prosecution environment.
The interview lift for Hastings is 40.2 percent, which is a strong indicator of the impact of verbal communication. This lift suggests that practitioners can increase their chances of an allowance by engaging in a direct dialogue compared to the 63.5 percent baseline. The median time to allowance is 1208 days, which is a duration for successful cases. Utilizing the 40.2 percent lift may help in navigating the 1208 days timeline more effectively in Art Unit 1627. These figures are essential for strategic planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18513606 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | Non-Final OA | FUJIFILM Corporation |
| 18290347 | NEW SUBSTITUTED PYRIDINES AS FUNGICIDE | Final Rejection | BASF SE |
| 18705802 | AGROCHEMICAL FORMULATIONS FOR MITIGATING CRYSTALLIZATION | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18812842 | DOSING REGIMEN OF HIV CAPSID INHIBITOR | Non-Final OA | Gilead Sciences, Inc. |
| 18004656 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | Non-Final OA | Purdue Research Foundation |
| 17996898 | COMPOUNDS FOR THE TREATMENT OF SARS | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18719582 | COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18251868 | INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | Final Rejection | Brown University |
| 18270581 | USE OF KRAS G12C INHIBITOR IN TREATING CANCERS | Final Rejection | AMGEN INC. |
| 18704133 | Novel Lipids For Delivery Of Nucleic Acid Segments | Non-Final OA | ASTRAZENECA AB |
| 18898082 | MYST Inhibitors | Non-Final OA | Isosterix, Inc. |
| 18728577 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Non-Final OA | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company |
| 17920992 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | Final Rejection | TXINNO BIOSCIENCE INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy